In patients with non–small cell lung cancer, CRP flare-response kinetics already occur in a substantial proportion of patients within a period of only 4 to 6 weeks.15 In the IMmotion150 study, on-treatment mGPS provides valuable prognostic information as early as 6 weeks after therapy initiation. This evidence concerns the gene CRP and lung cancer.